Language:
Instant News and Commentaries
2026-08-07
09:15
SpaceX and Tesla to Initially Pump USD16.8B in Texas Chip Gigafactory

SpaceX (SPCX.US) and Tesla, Inc. (TSLA.US) will initially invest USD16.8 billion to build the advanced AI semiconductor gigafactory Terafab in Grimes County, Texas, aiming to narrow the gap between global chip supply and the 1 trillion-watt computing capacity expected to be required by the two companies over the coming years.

SpaceX said in a statement that future expansion phases could substantially increase the total investment amount, and the plant is expected to employ at least 3,000 workers.

Elon Musk said Terafab is bringing cutting-edge manufacturing back to the US, creating thousands of high-paying jobs in Texas and enabling the companies to mass produce AI chips for use on Earth and in space.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:10
LG Group Chairman to Meet NVIDIA Jensen Huang Next Week to Discuss Co-op on AI Infra/ Humanoid Robots

LG Group Chairman Koo Kwang-mo will meet NVIDIA Corporation (NVDA.US) CEO Jensen Huang in the US next week to strengthen cooperation in AI infrastructure and humanoid robots, Yonhap News Agency, citing sources, reported.

The two met in Seoul in early June this year, when Huang said NVIDIA would cooperate with LG Group on humanoid robots and next-generation data centers.

The two will discuss the scale of potential investments and the timetable for technology development during next week's meeting, sources said.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
2026-08-06
21:17
Zoomlion DV3504 Hybrid Tractor Shortlisted for Two Categories of TOTY 2027, Marking a Breakthrough for Chinese High-Horsepower Agricultural Machinery

NAPLES, Italy, Aug. 6, 2026 /PRNewswire/ -- Zoomlion's DV3504 hybrid tractor has been shortlisted for two categories of the prestigious Tractor of the Year 2027 (TOTY 2027) awards: HighPower (300 hp and above) and Sustainable.


Launched in 1998 and independently organised by Italy's agricultural machinery publication Trattori, TOTY is one of the most recognised professional awards in the global agricultural machinery industry. The 2027 edition attracted 23 tractors from 18 global brands, with evaluations conducted by an international jury of 26 independent agricultural machinery journalists from 25 countries.

The dual-category nomination represents a milestone for Chinese agricultural machinery. The DV3504 is the first Chinese high-horsepower tractor to enter the TOTY shortlist since the award's establishment, breaking a long-standing gap for Chinese heavy-duty tractors in this globally influential competition. It is also the first Chinese high-horsepower agricultural machine recognised by an international independent jury for its original hybrid and low-carbon technology solution.

Developed to meet the demands of large-scale farming operations, the DV3504 delivers 350 hp and is equipped with Zoomlion's self-developed MiDD (Meshed intelligent Direct Drive) distributed intelligent electric drive system. Based on a multi-motor direct-drive architecture, the system independently powers the tractor's travel, PTO and hydraulic functions, enabling modular continuously variable transmission while reducing mechanical transmission components by approximately 70%.

Unlike pure electric solutions that still face challenges in endurance and continuous high-load operation for heavy-duty agricultural applications, hybrid technology provides a balance of long operating range, strong power output and energy efficiency. The DV3504 reflects Zoomlion's strategic focus on hybrid power and intelligent technologies for premium agricultural equipment.

Leveraging technological capabilities accumulated from its construction machinery business, including new energy systems, intelligent control and advanced manufacturing, Zoomlion is accelerating the transformation of agricultural machinery toward higher performance and sustainability.

Following its debut at AGRITECHNICA 2025 in Hanover, Germany, Zoomlion has achieved a significant step forward in its global agricultural machinery expansion — moving from an international exhibitor to a shortlisted contender in a leading global industry award within one year.

The final winners of TOTY 2027 will be announced at EIMA International in Bologna in November 2026.

Information Provided by PR Newswire [Disclaimer]
20:00
Kingsoft Cloud to Report Second Quarter 2026 Financial Results on August 19, 2026

BEIJING, Aug. 6, 2026 /PRNewswire/ -- Kingsoft Cloud Holdings Limited (NASDAQ: KC and HKEX: 3896) ("Kingsoft Cloud" or the "Company"), a leading cloud service provider in China, today announced that it will release its unaudited financial results for the second quarter 2026 ended June 30, 2026 before the open of U.S. markets on Wednesday, August 19, 2026.

The Company's management will host an earnings conference call on Wednesday, August 19, 2026 at 8:15 am, U.S. Eastern Time (8:15 pm, Beijing/Hong Kong Time on the same day).

Conference Call Registration

For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time.

https://register-conf.media-server.com/register/BIf61186884fdb445fabf9794d01884399

Upon registration, each participant will receive access details for this conference including a conference access code, a PIN number (personal access code), the dial-in number, and an e-mail with detailed instructions to join the conference call.

Additionally, a live and archived webcast of the conference call will be available at the Company's investor relations website at http://ir.ksyun.com.

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud Holdings Limited (NASDAQ: KC and HKEX: 3896) is a leading cloud service provider in China. Kingsoft Cloud has built a comprehensive and reliable cloud platform consisting of extensive cloud infrastructure, cutting-edge cloud products and well-architected industry specific solutions across public cloud and enterprise cloud.

For more information, please visit: http://ir.ksyun.com.

For more information, please contact:

Kingsoft Cloud Holdings Limited
Email:
[email protected]

Information Provided by PR Newswire [Disclaimer]
19:00
再鼎醫藥公佈2026年第二季度財務業績及近期公司進展

  • 公司已推進多個全球腫瘤和免疫管線項目邁向關鍵臨床和註冊里程碑,預計2026年下半年將迎來多個重要的管線催化劑
  • Zocilurtatug pelitecan(zoci)聯合PD-L1抑制劑用於一線小細胞肺癌(SCLC)的全球1期數據將在2026年ESMO大會上公佈;計劃將於今年晚些時候啟動一項註冊性3期研究
  • 評估zoci用於二線及以上SCLC的註冊性3期研究DLLEVATE進展順利,預計將於2027年上半年完成患者入組,以支持有望於2027年在美國提交的一項加速批准申請
  • ZL-1503(一款用於治療特應性皮炎的具有同類首創潛力的長效IL-13/IL-31Rα雙特異性抗體)全球1/1b期研究持續推進,預計將於2026年下半年獲得初步首次人體數據
  • 呫諾美林曲司氯銨(凱捷樂® )在中國內地成功上市,早期上市表現令人鼓舞,正在形成增長勢頭,為有望納入NRDL奠定基礎
  • 2026年第二季度總收入為1.063億美元;淨產品收入環比增長11%,得益於則樂的穩定表現以及艾加莫德銷量實現兩位數增長;商業化業務有望在2027年恢復顯著增長

公司將於今日202686日美國東部時間上午8:00(香港時間晚上20:00)舉行電話會議和網絡直播

中國上海和美國馬薩諸塞州劍橋市2026年8月6日 /美通社/ -- 再鼎醫藥有限公司(納斯達克股票代碼:ZLAB;香港聯交所股份代號:9688)今日公佈了2026年第二季度財務業績以及近期產品亮點和公司進展。

再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:「再鼎醫藥正在邁入一個令人振奮的新篇章。過去幾年,我們從將創新藥物帶給中國患者,逐步成長為一家為全球患者開發我們自己的差異化藥物的全球生物製藥公司。如今,我們的創新管線正快速走向成熟。我們在不到兩年時間內,將潛在同類最優DLL3抗體藥物偶聯物(ADC)zocilurtatug pelitecan(zoci)從新藥臨床試驗申請(IND)推進至全球3期臨床研究,而我們包括ZL-1503在內的不斷壯大的內部開發產品組合,讓我們堅信,創新將日益成為驅動再鼎醫藥下一階段增長的核心動力。與此同時,我們持續強化商業化業務。本季度,我們進一步聚焦商業化重點,實現環比收入增長,保持商業化盈利,為2027年恢復顯著增長奠定了基礎。所有這些成就,都助力再鼎醫藥為患者和股東創造長期價值。」

再鼎醫藥總裁、全球研發負責人Rafael G. Amado博士表示:「我們為公司不斷壯大的全球管線的進展深感振奮,預計到年底將有三項註冊性研究在開展中,並有望在明年提交我們的首個美國上市許可申請。Zoci已展現出差異化特徵——強大的全身和顱內活性以及良好的安全性特徵——支持其在小細胞肺癌(SCLC)和肺外神經內分泌癌(epNECs)多種治療場景中的開發。在免疫領域,ZL-1503有望通過IL-13和IL-31雙重抑制來同時解決炎症和瘙癢。結合YTE改造帶來的半衰期延長特性,我們相信其差異化特性有望在免疫領域的最大市場之一解決重大未滿足醫療需求。我們期待在今年下半年陸續分享這兩個項目的重要臨床更新。」

2026年第二季度財務業績

  • 2026年第二季度總收入為1.063億美元,2025年同期為1.1億美元。2026年第二季度產品收入淨額為1.058億美元,2025年同期為1.091億美元。產品收入淨額環比增長11%,得益於則樂的穩定表現以及艾加莫德的銷量持續增長。2026年下半年,我們期待進一步穩定產品銷量,為2027年恢復顯著增長奠定基礎。
  • 2026年第二季度的研發開支為6,180萬美元,2025年同期為5,060萬美元。這一增長主要是由於許可和合作協議的許可費用的增加,部分被臨床和臨床前成本下降抵銷。
  • 2026年第二季度的銷售、一般及行政(SG&A開支為7,290萬美元,2025年同期為7,100萬美元。SG&A開支同比基本持平,反映出公司在精簡組織、優化資源配置及提升運營效率方面的持續努力,以推動下一階段增長。
  • 2026年第二季度經營虧損為7,650萬美元,經調整後扣除折舊、攤銷和以股份為基礎的酬金等非現金支出後為虧損6,040萬美元。本新聞稿末尾附有經營虧損(美國公認會計準則)與調整後經營虧損(非美國公認會計準則)的對比。
  • 2026年第二季度虧損淨額為5,080萬美元,歸屬於普通股股東的每股普通股虧損為0.05美元(每份美國存托股份(ADS)虧損為0.46美元),2025年同期虧損淨額為4,070萬美元,每股普通股虧損為0.04美元(每份ADS虧損為0.37美元)。虧損淨額的增加主要是由於許可費用的增加。
  • 截至2026年6月30日,現金及現金等價物、短期投資及流動受限制現金總計為7.175億美元,截至2026年3月31日為7.613億美元。

近期管線亮點

以下是自上次財報發佈以來的關鍵候選產品進展:

腫瘤管線

  • Zocilurtatug Pelitecanzoci,靶向DLL3ADC)(前稱ZL-1310):
    • 2026年7月,再鼎醫藥獲得美國食品藥品監督管理局(FDA)授予zoci用於治療神經內分泌癌(NECs)的孤兒藥資格認定(ODD)。
    • 2026年6月,再鼎醫藥獲得歐洲藥品管理局(EMA)授予zoci用於治療肺神經內分泌癌患者的孤兒藥資格認定。
    • 2026年5月,再鼎醫藥獲得美國FDA授予zoci用於治療肺外神經內分泌癌(epNECs)患者的快速通道資格認定(FTD)。這是zoci獲得的第二項FDA快速通道資格認定,我們正在積極與監管機構溝通,推進用於治療epNECs註冊方案。
    • 2026年4月,再鼎醫藥合作夥伴安進啟動了全球1b期研究(DeLLphi-313)的入組,評估zoci聯合塔拉妥單抗(聯合或不聯合抗PD-L1)用於治療小細胞肺癌(SCLC)患者。
  • 緹樂(維替索妥尤單抗,組織因子ADC):
    • 2026年6月,中國國家藥品監督管理局(NMPA)批准了緹樂用於治療化療期間或之後疾病進展的復發或轉移性宮頸癌成人患者的生物製品上市許可申請(BLA)。緹樂是首個在中國獲批用於該適應證的ADC。

免疫、神經科學和感染性疾病領域管線

  • ZL-1503IL-13/IL-31Rα):已完成 ZL-1503 在健康志願者中開展的 1/1b 期研究單次給藥劑量遞增(SAD)部分的入組,初步藥代動力學(PK)、藥效學(PD)、安全性及免疫原性數據預計將於 2026 年下半年公佈。該研究用於特應性皮炎患者的多次給藥劑量遞增(MAD)部分的入組工作正在進行中。
  • 艾加莫德(FcRn):2026年5月,美國FDA批准了再鼎醫藥合作夥伴argenx提交的VYVGART®(艾加莫德靜脈輸注劑型)和VYVGART Hytrulo®(艾加莫德皮下注射劑型)的補充生物製品上市許可申請(sBLA),將其適應證拓展至涵蓋所有血清型的全身型重症肌無力(gMG)成人患者——抗AChR-Ab陽性、抗MuSK-Ab陽性、抗LRP4-Ab陽性以及三重血清陰性。該批准基於3期研究ADAPT SERON的數據。再鼎醫藥在大中華區參與了ADAPT SERON研究。再鼎醫藥正在開展準備工作,推動衛力迦於2027年納入中國國家醫保藥品目錄。
  • 呫諾美林曲司氯銨(M1/M4激動劑):2026年6月,再鼎醫藥在中國內地商業化上市呫諾美林曲司氯銨膠囊(凱捷樂®),用於治療成人精神分裂症。呫諾美林曲司氯銨是70多年來首個獲批的具有全新作用機制的精神分裂症療法,通過選擇性激活M1和M4毒蕈鹼受體,為治療精神分裂症提供了全新方法。再鼎醫藥正在準備,以尋求呫諾美林曲司氯銨於2027年被納入中國國家醫保藥品目錄的機會。
  • PovetaciceptpoveAPRIL/BAFF):2026年6月,再鼎醫藥合作夥伴Vertex宣佈美國FDA已受理pove用於免疫球蛋白A腎病(IgAN)成人患者的生物製品上市許可申請,並納入加速審批程序,處方藥用戶付費法案(PDUFA)目標行動日期為2026年11月30日。再鼎醫藥在大中華區參與了全球3期研究RAINIER。

2026年及2027年上半年預期重要里程碑

全球管線 
預期臨床進展和數據讀出

Zocilurtatug Pelitecanzoci,靶向DLL3ADC,前稱ZL-1310

  • 一線廣泛期小細胞肺癌(ES-SCLC:預計將於2026年10月歐洲腫瘤內科學會(ESMO)大會上報告zoci聯合阿替利珠單抗(聯合或不聯合化療)的1期初步數據,並依據後續數據和監管機構進行討論,於2026年下半年啟動一項註冊性3期研究。
  • 二線及以上ES-SCLC:預計將於2027年上半年完成全球關鍵性3期研究DLLEVATE入組,隨後是一項計劃中的中期分析,該中期分析數據有望支持提交一項加速批准的生物製品上市許可申請。
  • 肺外神經內分泌癌(epNECs:預計完成正在進行的全球1b/2期研究2期擴展部分的入組,評估zoci用於治療特定實體瘤患者,並根據監管機構的反饋,於2026年下半年推進該項目進入註冊性開發階段。

ZL-1503IL-13/IL-31Rα

  • 預計於2026年下半年報告用於健康志願者的全球1/1b期研究單次遞增劑量(SAD)部分的初步首次人體數據,包括藥代動力學(PK)、半衰期、藥效動力學生物標誌物(包括pSTAT6)和安全性。
  • 繼續開展用於特應性皮炎患者的1/1b期研究多次遞增劑量(MAD)部分的入組。MAD部分的初步臨床數據預計將於2027年上半年獲得。

ZL-6201LRRC15 ADC

  • 預計於2027年上半年提供評估ZL-6201用於肉瘤和特定腫瘤患者的全球1a/b期研究劑量遞增部分的主要結果。

ZL-1222PD-1/IL-12

  • 預計於2027年在美國提交一項新藥臨床試驗申請,並啟動一項全球1期研究。

ZL-1311MUC17/CD3

  • 預計於2026年底前在美國提交一項新藥臨床試驗申請,並於2027年上半年啟動一項全球1期研究。

區域管線
有望獲得NMPA受理的上市許可申請

  • 腫瘤電場治療(TTFields用於局部晚期胰腺癌

預期臨床開發和數據讀出
艾加莫德(FcRn

  • 肌炎:再鼎醫藥合作夥伴argenx將於2026年第三季度提供評估自身免疫性炎症性肌病(AIM或肌炎)的全球2/3期研究ALKIVIA的主要結果。再鼎醫藥在大中華區參與了ALKIVIA研究。

Elegrobart(抗IGF-1R,皮下注射)

  • 再鼎醫藥將於2026年第三季度完成用於治療甲狀腺眼病的中國3期註冊性研究的入組。
  • 再鼎醫藥將於2027年提供中國3期註冊性研究的主要結果。

電話會議和網絡直播信息

再鼎醫藥將於今日(2026年8月6日)美國東部時間上午8:00(香港時間晚上20:00)舉行電話會議和網絡直播。與會者可以訪問公司網站http://ir.zailaboratory.com參與實時網絡直播。如要參加電話會議,需提前註冊。

詳情如下:

所有參會者必須在電話會議之前通過以上鏈接完成在線註冊。註冊成功後,參會者將收到確認郵件,內含撥號接入詳情。

會議結束後不久,您可通過訪問再鼎醫藥網站觀看回放。

關於再鼎醫藥

再鼎醫藥(納斯達克股票代碼:ZLAB;香港聯交所股份代號:9688)是一家以研發為基礎、處於商業化階段的創新型生物製藥公司,總部位於中國和美國。我們致力於通過創新產品的發現、開發和商業化解決腫瘤、免疫、神經科學和感染性疾病領域未被滿足的巨大醫療需求。我們的目標是利用我們的能力和資源為人類健康帶來積極影響。

有關再鼎醫藥的更多信息,請訪問www.zailaboratory.com或關注公司官微:再鼎醫藥。

非美國公認會計準則指標

除了根據美國公認會計準則呈現的業績外,我們還披露了經調整的增長率,以排除由於外幣折算為美元產生差異的影響。我們還提供了調整後的經營虧損指標,該指標對美國公認會計準則經營虧損進行了調整,以排除某些非現金支出(包括折舊、攤銷、以及以股份為基礎的酬金)的影響。我們稱之為「實現非美國公認會計準則經營利潤盈利」。這些調整後的增長率和調整後的經營虧損是非美國公認會計準則指標。我們認為這些非美國公認會計準則指標對於瞭解我們的經營業績和財務業績非常重要,並為投資者提供了趨勢的更多視角。儘管我們認為非美國公認會計準則財務指標可以增強投資者對我們業務和業績的瞭解,但這些非美國公認會計準則財務指標不應被視為相應的美國公認會計準則財務指標的唯一替代指標。

再鼎醫藥前瞻性聲明

本新聞稿包含了與以下方面相關的前瞻性陳述,包括:我們的策略和計劃;我們的業務、商業化產品和管線項目的潛力和預期;我們的目標、目的和重點事項以及我們基於增長戰略的預期(包括我們對商業化產品和上市、臨床階段產品、收入增長、盈利能力和現金流的預期);臨床開發計劃和相關臨床研究;臨床研究數據、數據解讀和發佈;與藥物開發和商業化相關的風險和不確定性;註冊相關的討論、提交、申請、獲批和時間線;我們及我們合作夥伴的產品和候選產品的潛在裨益、安全性和有效性;投資、合作和業務拓展活動的預期收益和潛力;我們的盈利能力和實現盈利的時間線;我們未來的財務和經營業績;以及財務指導(包括我們的資本配置和投資策略以及我們預期實現盈利的途徑)。除對過往事實的陳述外,本新聞稿中包含的所有陳述均屬前瞻性陳述,並可通過諸如「旨在」、「預計」、「認為」、「有可能」、「估計」、「預期」、「預測」、「目標」、「打算」、「可能」、「計劃」、「準備」、「定位」、「可能的」、「潛在」、「將會」、「將要」等詞彙和其他類似表述予以識別。該等陳述構成《1995年美國私人證券訴訟改革法案》中定義的「前瞻性陳述」。前瞻性陳述並非對未來表現的擔保或保證。前瞻性陳述基於我們截至本新聞稿發佈之日的預期和假設,並且受到固有不確定性、風險以及可能與前瞻性陳述所預期的情況存在重大差異的情勢變更的影響。對於我們在前瞻性陳述中披露的計劃、意圖、預期或預測,我們可能無法實際實現、執行或滿足,請勿過分依賴此等前瞻性陳述。實際結果可能受各種重要因素的影響而與前瞻性陳述所示存在重大差異,該等因素包括但不限於:(1)我們成功商業化自身已獲批上市產品並從中產生收入的能力;(2)我們為自身的運營和業務活動獲取資金的能力;(3)我們候選產品的臨床開發和臨床前開發的結果;(4)相關監管機構對我們的候選產品作出審批決定的內容和時間;(5)與在中國營商有關的風險;和(6)我們向美國證券交易委員會(SEC)提交的最新年報和季報以及其他報告中指出的其他因素。我們預計後續事件和發展將導致我們的預期和假設改變,但除法律要求之外,不論是出於新信息、未來事件或其他原因,我們均無義務更新或修訂任何前瞻性陳述。該等前瞻性陳述不應被視為我們在本新聞稿發佈之日後任何日期的意見而加以信賴。

如需查閱公司向SEC提交的文件,請訪問公司官網www.zailaboratory.com和SEC網站www.sec.gov

Information Provided by PR Newswire [Disclaimer]
17:51
Scaling Autonomous Freight: Inside Pony.ai's Robotruck Business

From Gen-4 heavy-duty trucks to L4 urban delivery vehicles, shared technology, automotive-grade production and industry partnerships are shaping the next phase of Pony.ai's autonomous freight business

GUANGZHOU, CHINA, Aug. 6, 2026 /PRNewswire/ -- At a media briefing on August 3, He Xing, Vice President of Pony.ai and Head of the company's Robotruck business, discussed how nearly a decade of technology development in L4 autonomous driving is beginning to support broader commercial deployment in freight transportation.

Over the next two to three years, Pony.ai expects 500 to 1,000 Gen-4 autonomous heavy-duty trucks to be deployed across three primary scenarios in China: long-haul freight, bulk commodity transportation and port logistics. Pony.ai also expects light-duty trucks to scale faster, with a longer-term goal of reaching 100,000 L4 autonomous light-duty trucks by 2030.

The targets reflect several developments coming together: a more mature autonomous driving system, lower hardware costs, automotive-grade redundant vehicle platforms and deeper collaboration with vehicle manufacturers and logistics operators.

Why freight, and why now

Pony.ai began developing autonomous trucks in 2018. The first vehicles were largely hand-built prototypes. Subsequent generations moved progressively closer to automotive-grade production through partnerships with truck manufacturers. The question gradually shifted from whether the technology could work to where and under what conditions, it could create the most operational value.

Road freight presents a clear need. The industry faces persistent structural pressures, including a shortage of qualified heavy-duty truck drivers, an aging workforce and sharp fluctuations in demand during peak seasons. Long hours, overnight driving and demanding routes can also increase fatigue-related safety risks. L4 autonomy can help supplement freight capacity, particularly on repetitive routes and during overnight or peak-demand periods that are difficult to staff, while supporting safer, more consistent operations.

Turning that potential into scaled operations, however, requires more than technical capability. Autonomous driving systems must also be safe, reliable, ready for automotive-grade production and commercially viable at scale. For Pony.ai, the timing of large-scale deployment has therefore also depended on bringing down the cost of the autonomous driving system.

"We had been waiting for the right moment," He said. "Our truck technology had already reached a high level, but the cost of building an L4 Robotruck remained high. The reduction in ADK costs benefited both heavy- and light-duty trucks. That is why we did not rush into large-scale production earlier."

Pony.ai's Gen-4 autonomous heavy-duty truck has reduced autonomous driving hardware costs by approximately 70% compared with the previous generation. Developed for automotive-grade mass production, the vehicle is designed for a service life of 20,000 operating hours or up to 1 million kilometers.

The Robotruck business has already moved beyond technology testing. As of November 2025, Pony.ai operated a fleet of around 200 trucks and had transported more than 1 billion ton-kilometers of freight. In the first quarter of 2026, Robotruck services generated US$10.2 million in revenue, up 31% from a year earlier, driven primarily by the expansion of commercial operations.

Two vehicle platforms across the freight network

Pony.ai's current Robotruck strategy covers both heavy-duty trucks and light-duty trucks, reflecting the different roles they play across the freight network.

Heavy-duty trucks are designed primarily for transportation between logistics hubs, including long-haul highway freight, bulk commodity routes and port transportation. Pony.ai's Gen-4 models are based on battery-electric platforms and support both single-vehicle autonomous operation and L4 platooning, depending on the requirements of each operating environment.

Production of the Gen-4 heavy-duty trucks is now underway. Vehicles are expected to roll off the production line in batches and enter commercial service across several use cases over the coming months.

Shenzhen's Mawan Port will be among the first deployment sites. Pony.ai has secured a project there and expects to deploy dozens of Gen-4 Robotrucks for commercial operations. Ports represent one of the three priority scenarios for the platform, alongside highway freight and bulk commodity transportation in western China.

Light-duty trucks address a different part of the logistics chain. They are commonly used between urban distribution centers, retail stores, delivery outlets and cold-chain facilities—environments that overlap substantially with the complex urban road conditions in which Pony.ai's Robotaxis already operate.

Pony.ai introduced its first L4 autonomous light-duty truck in April 2026. Co-developed with CATL and built on CATL's Kunshi Chassis Platform, the vehicle uses automotive-grade components and a fully redundant safety architecture. It offers approximately 18 cubic meters of cargo space and is intended for both urban and intercity freight.

The first vehicles have now entered intensive road testing in operating environments provided by logistics partners. Initial use cases include express delivery, retail distribution and food and beverage cold-chain logistics. Pony.ai plans to pursue the regulatory approvals required for fully driverless operation as testing and validation progress.

Based on current operating assumptions, Pony.ai estimates that fully driverless light-duty trucks could reduce per-kilometer operating costs by 40% to 50% compared with conventional human-driven operations. The vehicle can also carry 2.6 times the cargo volume of mainstream low-speed autonomous delivery vehicles, while operating at speeds suitable for regular urban and intercity roads.

One Virtual Driver across vehicle types

Pony.ai's approach is built around applying the same underlying Virtual Driver technology across Robotaxis, heavy-duty trucks and light-duty trucks.

The light-duty truck uses the same core technology stack as Pony.ai's Gen-7 Robotaxi. Because the two platforms operate in many of the same urban environments, they can also share supporting infrastructure and operating capabilities, including charging, ground support, service centers, fleet management and remote assistance. Pony.ai estimates that the overall technological and operational synergies between the two platforms exceed 90%.

Heavy-duty trucks require more vehicle-specific adaptation. Their size, weight, mechanical structure and longer braking distances create different control requirements, while highway and bulk commodity routes introduce operating conditions not commonly encountered by passenger vehicles. Even so, the core capabilities used to understand traffic, interact with other road users and make driving decisions draw on the same underlying technology and development methodology.

Data and operating experience from the different vehicle platforms also contribute to a shared development loop. PonyWorld 2.0, Pony.ai's proprietary world model, is designed to identify areas where the Virtual Driver requires further improvement, guide targeted data collection and support more efficient training and evaluation.

"Autonomous driving has to progress step by step—from technology driving product development, to the product enabling a business model, and ultimately to that model reshaping the industry," He said.

The shared safety architecture is equally important. Pony.ai's current Robotaxi, heavy-duty truck and light-duty truck platforms use redundant systems covering steering, braking, communication, power supply, computing and sensing. This fail-operational design allows a vehicle to maintain core driving functions and select an appropriate location to pull over safely if certain hardware or software components fail.

A partner-led route to scale

Scaling autonomous freight requires more than producing vehicles. It also requires access to freight demand, established operating networks, maintenance capabilities and infrastructure such as logistics hubs and charging facilities.

Pony.ai has therefore built its Robotruck business around partnerships with vehicle manufacturers and logistics operators. Its Gen-4 heavy-duty trucks were developed in collaboration with manufacturers including SANY Truck, while the light-duty truck was co-developed with CATL. Pony.ai also works with Sinotrans across long-haul freight and urban logistics scenarios.

The commercial model can vary depending on the maturity and requirements of a project. In some earlier-stage deployments, Pony.ai participates more directly in vehicle ownership and freight operations through a Transportation-as-a-Service, or TaaS, model. This allows the company and its partners to validate operating performance and unit economics in real commercial environments.

As the market matures, Pony.ai expects partner-led deployment under an Autonomous Driving-as-a-Service, or ADaaS, model to play a larger role. Under this model, vehicle manufacturers produce the trucks, logistics partners own and operate the fleets, and Pony.ai provides its Virtual Driver and related technical services. Some port projects are already beginning to adopt this approach.

"We are not here to run e-commerce or postal services ourselves," He said. "Our role is to become a partner to logistics companies and integrate into the systems they already use to serve their customers."

This structure allows each participant to focus on its established strengths: vehicle manufacturers on automotive-grade production and sales, logistics companies on freight demand and fleet operations, and Pony.ai on autonomous driving technology.

The next phase

The next phase of Pony.ai's Robotruck business will focus on ramping up production of the Gen-4 heavy-duty truck and deploying it in commercial projects, while completing the testing and regulatory work required to deploy the light-duty truck at scale.

In heavy-duty trucking, Pony.ai will initially focus on highway freight corridors, bulk commodity routes and ports. The company is also exploring an innovative model for highway transportation, which could simplify trailer handoffs between autonomous highway operations and human-driven first- and last-mile delivery.

For light-duty trucks, the immediate focus is to work with logistics partners to validate operations in express delivery, retail distribution and cold-chain transportation. The ability to operate overnight when drivers are more difficult to recruit and fatigue-related safety risks are higher could become an early commercial use case.

Pony.ai also sees potential for autonomous trucks in overseas markets, particularly at ports and other well-defined logistics sites where driver shortages and labor costs strengthen the economics of automation.

For Pony.ai, the objective is not simply to place more autonomous trucks on the road. It is to build a repeatable operating model in which technology, vehicles, infrastructure and freight demand can scale together.

Information Provided by PR Newswire [Disclaimer]
16:50
TSMC Reportedly Hit by DRAM Supply Woe; Apple Chips Unable to Be Packaged

With less than six weeks remaining before the launch of Apple Inc. (AAPL.US)'s iPhone 18 series and foldable iPhone Ultra, TSMC (TSM.US) hit snags while producing Apple's A20 Pro chips, independent technology journalist Tim Culpan said.

An acute shortage of DRAM memory has prevented completed processor wafers from being packaged, heaping tremendous pressure on Apple's supply chain.

Apple has mainly relied on Micron Technology, Inc. (MU.US) for DRAM chip supply, while also sourcing from SK Hynix and Samsung.

Apple and its assemblers are reportedly scrambling to secure sufficient DRAM chips in order to avoid severe supply pressure during the launch of the iPhone 18 series.
~


AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
13:54
復星國際榮膺《全球銀行與金融評論》三項大獎,ESG、企業社會責任及品牌實力再獲國際權威認可

香港2026年8月6日 /美通社/ -- 近日,英國知名金融行業雜誌《全球銀行與金融評論》(Global Banking and Finance Review)公佈2026年度獲獎名單,復星國際有限公司(香港聯交所股份代號:00656)憑借在可持續發展與企業社會責任領域的卓越貢獻,以及日益提升的全球品牌影響力,一舉斬獲三項大獎。

復星國際此次榮獲:「ESG及可持續發展獎-2026年亞洲最佳可持續發展企業獎」、「企業社會責任獎-2026年亞洲最佳企業社會責任公司獎」及「品牌獎-2026年亞洲最佳控股集團品牌獎」,充分印證了復星在可持續發展戰略執行、公司治理體系完善、社會責任履行及環境保護等維度所取得的進展,亦是對其長期以來堅持透明化運營、積極構建利益相關方溝通機制的整體肯定。

《全球銀行與金融評論》指出,復星國際此次獲獎,源於其在多個維度的均衡發展與突出表現:在業務層面,復星通過持續優化全球產業生態佈局,實現了核心業務的穩健增長與抗週期韌性;在可持續發展層面,公司將ESG理念深度融入戰略決策與日常運營,展現出清晰的路徑規劃與堅定的執行決心。評委會特別強調,復星在推動商業價值與社會價值協同發展方面的實踐,為亞洲乃至全球的企業提供了有益參照。

ESG評級屢獲佳績,可持續發展戰略深入推進

復星已將可持續發展提升至企業戰略核心,並提出了「創造影響力」(Create IMPACT)的可持續發展戰略,明確了創新驅動、責任運營、以人為本、精益治理、綠色發展和透明真實六大長期方向。2026年度,復星在ESG領域迎來全面突破:其MSCI ESG評級躍升至最高的AAA級,這是自2021年獲評AA以來歷經五年深耕實現的重大跨越,標誌着綜合管理水平達到全球同業領先水平。與此同時,復星在富時羅素ESG評分中升至4.2分(滿分5分),並連續第五次入選「富時羅素社會責任指數」成份股,在國際權威指數機構的評級體系中持續保持領先身位。

國際主流可持續發展評估持續提升,復星成功入選標普全球《可持續發展年鑑2026》,並在《可持續發展年鑑(中國版)2026》中連續第三年名列中國最佳1%。此外,復星還斬獲了香港管理專業協會「卓越環境、社會及管治報告嘉許獎」、《金融衍生工具》雜誌「香港最佳ESG公司」獎、《財富》「最受贊賞中國公司榜單『行業明星榜,以及亞洲企業管治』亞太區可持續發展大獎」和「最佳環境責任獎」等一系列獎項,充分展現了業界對復星全方位ESG工作的高度認可。

立業為善,積極回饋社會

作為負責任的企業公民,復星於2012年成立復星基金會,在全球應急馳援、鄉村振興、健康醫療、教育文化等領域持續創造社會價值。

復星不斷深耕鄉村振興與基層健康領域,「鄉村醫生計劃」自2017年啓動以來,已累計守護2.5萬名鄉村醫生,惠及300萬戶農村家庭,該項目更入選了聯合國全球契約組織「二十年二十佳」企業可持續發展案例。復星國際董事長郭廣昌不久前專程前往江西廣昌縣,回訪了復星鄉村醫生項目已守護九年的村醫老友,他感慨道:「每次跟這些鄉村醫生聊完,都覺得這件事做對了,這是復星做公益的初心。」管理層身體力行的長期關注,正不斷為項目注入持續前行的動力。2026年第二季度,「AI村醫助手2.0」正式發佈,新增化驗單與體檢報告智能解讀功能,並以更貼合村醫實際工作場景的交互體驗,切實提升基層診療效率。

面對突發災情,復星基金會展現出高效的響應能力。2026年7月,廣西遭遇罕見洪澇災害,基金會第一時間啓動馳援機制,近60萬件救援物資迅速送抵一線,以「快0.01秒」的專業行動為受災群眾和救援隊伍提供發電機、自熱飯等急需保障,生動詮釋了其始終如一的公益初心與執行力。

復星持續助力青年創業及全球創新,復星基金會聯合復星葡萄牙保險Fidelidade、葡萄牙醫療集團Luz Saúde等機構共同發起的第八屆「Protechting全球青年創新創業大賽」再創佳績。賽事聚焦保險科技、醫療科技、人工智能及ESG可持續發展等前沿領域,共吸引來自50餘個國家和地區的637個項目申請,數量創歷史新高;賽事不僅為入圍團隊提供80餘場導師面對面及企業深潛日等深度孵化支持,還積極搭建中歐創新橋樑——13支國際科創團隊將受邀參加2026年金秋中國路演,前往香港、佛山、澳門、珠海、上海等地對接產業資源與投資機構。從葡萄牙到中國,Protechting持續構建跨越洲際的科創交流平台,讓全球青年創新力量在中國及國際市場生根發芽,踐行「科創+公益」模式的長期承諾。

創新驅動發展,AI與健康領域惠及民生

復星始終堅持「以解決實際問題為出發點」,將人工智能深度融入醫藥健康與智慧服務等核心產業。在研發端,復宏漢霖AI蛋白藥物智能設計平台僅用3個月便將核心項目藥物分子親和力提升20倍以上,大幅加速新藥問世;在服務端,復星旅文推出「AI G.O」智能管家,將傳承數十年的非標服務經驗轉化為7X24小時在線的數字資產,為遊客提供有溫度的個性化體驗。同時,復星還積極推動技術向善,其「AI村醫助手」已面向2.5萬名鄉村醫生推廣應用,以92%的用戶滿意度切實賦能基層醫療末梢,讓科技創新成果惠及最需要的人群。

復星旗下健康產業始終秉承為更多患者帶來治癒希望的初心,深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域,並積極拓展慢病及罕見病,打造具有長期競爭力的產品管線。持續夯實抗體、ADC、小分子、細胞治療等核心技術平台,並拓展核藥、小核酸等前沿技術,取得了一系列惠及全球患者的突破性成果:漢斯狀®作為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗,已在40餘個國家和地區上市;HLX43在非小細胞肺癌、婦科腫瘤等多個領域展現「高效、低毒」優勢;HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。

與此同時,復星醫藥致力於提升藥物可及性,為推動「無瘧疾世界」的全球願景持續貢獻中國力量,截至2025年底,其自主研發的注射用青蒿琥酯已累計救治全球超8,800萬重症瘧疾患者,累計供應超過4.4億支。

展望未來,復星國際將繼續深化「創造影響力」的可持續發展戰略,通過創新和負責任的運營,積極承擔更多社會責任,致力於創造更加負責任、包容和可持續的未來。

Information Provided by PR Newswire [Disclaimer]
13:17
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength

HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable development and corporate social responsibility (CSR), as well as its growing global brand influence.

Fosun International received the "ESG & Sustainability Awards – Best Sustainable Development Company Asia 2026", "CSR Awards – Best CSR Company Asia 2026", and "Brand of the Year Awards – Holding Group Brand of the Year Asia 2026". These accolades underscore the progress it has made in executing its sustainable development strategy, strengthening corporate governance, fulfilling its social responsibility and advancing environmental protection, while also affirming its long‑standing commitment to transparent operations and proactive stakeholder communication.

Global Banking and Finance Review highlighted that Fosun's recognition in these awards reflects its balanced development and outstanding performance across multiple areas. On the business front, Fosun has continued to optimize its global industrial ecosystem, delivering resilient growth in its core businesses and strengthening its ability to navigate economic cycles. On the sustainability front, the company has integrated ESG principles into both strategic decision-making and day-to-day operations, underpinned by a clear roadmap and strong execution. The judging panel particularly emphasized that Fosun's efforts to align commercial value with social value offer a valuable reference for companies in Asia and globally.

Outstanding ESG Performance and Continued Advancement of Sustainable Development Strategy

Fosun has embedded sustainable development at the heart of its corporate strategy and introduced the "Create IMPACT" sustainable development strategy, which sets out six long-term directions: Innovation-Driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency. In 2026, Fosun achieved a comprehensive breakthrough in Environmental, Social, and Governance (ESG) performance. Its MSCI ESG rating has been upgraded to the highest rating AAA, marking a significant milestone after five years of sustained effort since first receiving an AA rating in 2021 and indicating that its overall management standards have reached a leading position among global peers. Meanwhile, Fosun's FTSE Russell ESG score rose to 4.2 (maximum score: 5) and has been included in the FTSE4Good Index Series for the fifth consecutive time, maintaining a leading position in the rating systems of internationally recognized index providers.

Fosun has also achieved steady improvement in mainstream international sustainability assessments. It has been included in S&P Global's Sustainability Yearbook 2026 and, for the third consecutive year, ranked among the top 1% in the Sustainability Yearbook (China Edition) 2026. Furthermore, Fosun garnered a number of awards, including the "Certificate of Excellence in Environmental, Social and Governance Reporting" from Hong Kong Management Association, "Best ESG Company Hong Kong" from the magazine Financial Derivative, recognition in Fortune's "Most Admired Chinese Companies" list, and "Sustainable Asia Award" and "Best Environmental Responsibility Award" from Corporate Governance Asia, all of which underscore the industry's strong recognition of Fosun's comprehensive ESG efforts.

Fosun for Good, Actively Giving Back to Society

As a responsible corporate citizen, Fosun established Fosun Foundation in 2012, continuously creating social value in areas such as global emergency relief, rural revitalization, healthcare, and education and culture.

Fosun has continued to deepen its commitment to rural revitalization and primary healthcare. Since its launch in 2017, the Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families. The program was also selected as one of the UN Global Compact's "20 Cases of Private Sector's Sustainable Development in China for 20 Years". Recently, Guo Guangchang, Chairman of Fosun International, made a trip to Guangchang County, Jiangxi Province, to visit rural doctors who have been supported by Fosun's Rural Doctors Program for nine years. He said, "Every time I speak with rural doctors, I feel even more strongly that we are doing the right thing. This reflects Fosun's original aspiration in supporting philanthropy." The management's long-term commitment and hands-on approach have continued to drive the program forward. In the second quarter of 2026, Fosun launched "AI Rural Doctor Assistant 2.0", adding intelligent interpretation of lab reports and physical examination reports, alongside an interactive experience tailored to the actual workflows of rural doctors, thereby effectively enhancing primary healthcare efficiency.

In the face of sudden disaster, Fosun Foundation has demonstrated its efficient response capability. In July 2026, Guangxi was struck by a severe, devastating flood. Fosun Foundation immediately activated its emergency relief mechanism and rapidly delivered nearly 600,000 relief items to the front lines. Driven by a "0.01 second faster" mindset, it provided urgently needed supplies such as generators and self-heating meals to the affected people and rescue teams, demonstrating its enduring commitment to philanthropy and strong execution.

Fosun has also continued to support youth entrepreneurship and global innovation. The 8th edition of the "Protechting Open Innovation Program" jointly launched by Fosun Foundation, Fidelidade, and Luz Saúde, reached new heights this year. Focused on cutting-edge areas such as insurtech, medtech, artificial intelligence (AI), and ESG, the program received 637 applications from more than 50 countries and regions, setting a new record. In addition, the program provided deep incubation support, including over 80 mentor sessions and corporate immersion days for shortlisted teams. It also served as a bridge connecting Europe and China. Thirteen international technology innovation teams have been invited to participate in roadshows across Hong Kong, Foshan, Macau, Zhuhai, and Shanghai this autumn, where they will connect with industry resources and investment institutions. From Portugal to China, Protechting is steadily building an intercontinental platform for innovation exchange, helping young innovators from around the world to take root in China and beyond, and reflecting its long-term commitment to the "technology innovation + philanthropy" model.

Innovation-Driven Growth, Bringing AI and Healthcare Benefits to the Public

Fosun has consistently prioritized solving real-world problems and has deeply integrated AI into its core businesses, including pharmaceuticals, healthcare and intelligent services. On the research and development (R&D) front, Henlius' AI-powered protein drug design platform has increased the binding affinity of a core project molecule by more than 20 times in just three months, significantly accelerating the development of new drugs. On the service front, Fosun Tourism Group has launched the AI G.O intelligent system, transforming decades of non-standard service experience into a 24/7 digital asset to deliver more personalized and thoughtful experiences for guests. Fosun has also been actively advancing technology for social good. Its "AI Rural Doctor Assistant" has been rolled out to 25,000 rural doctors, with a user satisfaction rate of 92%, effectively empowering grassroots primary healthcare and bringing the benefits of technology innovation to those who need them most.

Fosun's Health business remains committed to bringing new hope of cure to more patients. It has established a deep presence in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, it continues to consolidate its core technical platforms including antibodies, antibody-drug conjugates (ADCs), small molecules and cell therapies, while expanding into cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. It has achieved a series of breakthroughs that are benefiting patients worldwide. As the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), HANSIZHUANG has been approved for marketing in over 40 countries and regions. HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, and other indications. HLX22 is the world's first anti-HER2-targeted therapy to receive Orphan Drug Designation (ODD) approvals from both the US Food and Drug Administration (FDA) and the European Commission (EC) for gastric cancer.

At the same time, Fosun Pharma is committed to enhancing medication accessibility and contributing to the global vision of a "malaria-free world". As of the end of 2025, Fosun Pharma's independently developed artesunate for injection had saved more than 88 million patients with severe malaria worldwide, with more than 440 million vials supplied globally.

Looking ahead, Fosun will continue to deepen its "Create IMPACT" sustainable development strategy, actively taking on greater social responsibility through innovation and responsible operations, and endeavoring to build a more responsible, inclusive, and sustainable future.

Information Provided by PR Newswire [Disclaimer]
12:24
NVIDIA Reportedly Seeks 6G Base Station Partners in CN, Aims to Enter Trial Networks as Early as 2027

NVIDIA Corporation (NVDA.US) is accelerating its foray into the telecom operator market and is seeking base station manufacturing partners in China to develop 6G base stations that meet overseas market requirements, with the aim of entering trial networks in 2027 or 2028, Jiemian News reported, citing sources.

NVIDIA purportedly believes computing power ultimately needs to rely on wireless transmission via base stations in order to transfer from data centers to massive numbers of AI terminals and users. The company is therefore searching for the “next ZJ INNOLIGHT (03308.HK)” in edge computing power.

Shenzhen Signalwing Technology is one of NVIDIA's developing base station partners, sources said. The two parties began contacts in 2025 and are jointly developing 6G AI-RAN base stations based on the NVIDIA CUDA ecosystem. Their cooperation has continued for more than six months, and a dedicated working group has already been formed, involving more than 10 NVIDIA personnel based in Singapore, Hong Kong and Mainland China.

TONGYU COMM (002792.SZ) acquired an approximately 25% stake in Shenzhen Signalwing Technology for RMB300 million on August 4.

Besides, the cooperation between Shenzhen Signalwing Technology and NVIDIA has reportedly entered the technology R&D stage. The duo may also establish a commercial entity jointly for overseas expansion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]